We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Dec 2021
  • Code : CMI4834
  • Pages :202
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Radiation and radioactive compounds play a crucial role in therapeutic and diagnostic approaches in oncology. From last few decades radiotherapy is used in cancer diagnostic and therapeutic applications.  Radiation therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.

The global oncology radiopharmaceuticals market is estimated to be valued at US$ 3,462.8 million in 2021 and is expected to exhibit a CAGR of 6.0% during the forecast period (2021-2028).

Figure 1. Global Oncology Radiopharmaceuticals Market in Terms of Value (US$ million), By Region, 2021

ONCOLOGY RADIOPHARMACEUTICALS MARKET

To learn more about this report, request a free sample copy

Emerging use of radiopharmaceuticals as new cancer therapy is expected to drive the global oncology radiopharmaceuticals market growth during the forecast period.

Radiopharmaceuticals deliver radiation therapy directly and specifically to cancer cells. Radioactive iodine are being used to treat some types of thyroid cancer since the 1940s. In the area of oncology, the use of radiopharmaceuticals has increased particularly for imaging, diagnosis, staging, and follow up. Players are focusing on research and clinical trials testing for new radiopharmaceuticals to address the emerging use of radiopharmaceuticals is expected to augment the growth of market. For instance, in 2018, the U.S. Food and Drug Administration approved Lutathera (lutetium Lu 177 dotatate) a radioactive element for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Lutathera was approved by the European Commission (EC) in September 2017.

Oncology Radiopharmaceuticals Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 3,462.8 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 45.7% 2027 Value Projection: US$ 5,206.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Test Type: Radium-223 dichloride, Sodium iodide I-131, Lobenguane iodine-131, Lutetium-177, Yttrium-90, Fludeoxyglucose F 18, Gallium Citrate Ga 67, Technetium-99m, Others
  • By Route of Administration: Oral, Intravenous
  • By Application: Diagnosis, Treatment
  • By End User: Diagnostic Centers, Hospitals and Clinics, Research Institutes
Companies covered:

Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health

Growth Drivers:
  • Increasing demand for radiopharmaceuticals in cancer therapy
  • Shift towards combination therapies
Restraints & Challenges:
  • Lack of skilled professionals

Figure 2. Global Oncology Radiopharmaceuticals Market Share (%), By Application, 2021

ONCOLOGY RADIOPHARMACEUTICALS MARKET

To learn more about this report, request a free sample copy

Shift towards combination therapies is expected to propel the global oncology radiopharmaceuticals market growth over the forecast period.

The use of radiopharmaceuticals in combination with other therapies to improve the treatment is likely fuel the growth of market.  A growing area of interest in radiopharmaceutical as a combination of a targeted therapeutic and diagnostic use is boost the growth of market. For instance, according to an article published in MEDPACE lutetium-177 and galium-68 are used together to diagnose and treat neuroendocrine tumors.

Global Oncology Radiopharmaceuticals Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 caused several challenges to cancer practices, especially to ensure continuity of treatment during this pandemic period. It has significantly affected healthcare systems and economies within a short timeframe. Radiation oncology departments are sensitive and dependent on diagnostic confirmation and therapeutic indication in cancer care. Moreover, the unprecedented demand for hospital services during the SARS-CoV-2 (COVID-19) pandemic has dramatically reduced the capability for dealing with non-acute health needs, including cancer care. Consecutively delay/decrease the number of cancer diagnostic cases is leads to hamper the market growth.

Global Oncology Radiopharmaceuticals Market: Restraints

Lack of trained professionals is one of the challenges that hamper the growth of the market. For instance, according to the National Cancer Institute, the number of nuclear medicine physicians who have training in both nuclear medicine and medical oncology is less in United States.

Key Players                   

Major players operating in the global oncology radiopharmaceuticals market include Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health.

Frequently Asked Questions

The global oncology radiopharmaceuticals market is estimated to be valued at US$ 3,462.8 million in 2021 and is expected to exhibit a CAGR of 6.0% between 2021 and 2028.

Increasing awareness regarding the radioactive compounds and their use in oncology are projected to boost the market growth over the forecast period.

Diagnosis segment is hold a major market share in the market.

The major factor hampering growth of the market include lack of trained workforce.

Major players operating in the market include Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo